Is Aveo Pharmaceuticals Inc (NASDAQ:AVEO)’s Fuel Running Low? Reports Show More Sellers

May 17, 2018 - By Paula Hilliard

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Logo

Investors sentiment increased to 2.81 in 2017 Q4. Its up 1.49, from 1.32 in 2017Q3. It is positive, as 4 investors sold AVEO Pharmaceuticals, Inc. shares while 12 reduced holdings. 26 funds opened positions while 19 raised stakes. 59.55 million shares or 0.59% less from 59.90 million shares in 2017Q3 were reported.
Northern Trust Corporation reported 206,033 shares. Granahan Inv Mgmt Incorporated Ma owns 136,908 shares. Polar Cap Limited Liability Partnership, United Kingdom-based fund reported 8.08 million shares. Citigroup owns 2,679 shares for 0% of their portfolio. Edge Wealth Lc invested 0.01% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Morgan Stanley has 138,926 shares. Glg L P, United Kingdom-based fund reported 25,200 shares. Manufacturers Life Insurance The reported 3,213 shares. Jump Trading Lc holds 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 11,939 shares. Citadel Advsr Ltd Llc holds 0% or 843,820 shares in its portfolio. Barclays Pcl accumulated 305,481 shares or 0% of the stock. 683 Cap Mgmt Lc holds 0.59% or 2.50M shares. Evercore Wealth Mngmt Llc reported 418,414 shares. New Leaf Venture Ltd has 964,520 shares for 1.26% of their portfolio. Venbio Select Advisor Ltd Llc has 0.72% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 4.01M shares.

Since April 6, 2018, it had 20 insider purchases, and 0 sales for $22.66 million activity. On Tuesday, May 8 the insider SANDELL SCOTT D bought $151,250. MOTT DAVID M bought $151,250 worth of stock. $151,250 worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was bought by Growth Equity Opportunities IV – LLC. BARRIS PETER J also bought $151,250 worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares. $151,250 worth of stock was bought by Viswanathan Ravi on Tuesday, May 8. $151,250 worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was bought by MAKOWER JOSHUA.

The stock of Aveo Pharmaceuticals Inc (NASDAQ:AVEO) registered an increase of 16.95% in short interest. AVEO’s total short interest was 9.84M shares in May as published by FINRA. Its up 16.95% from 8.42 million shares, reported previously. With 1.26M shares average volume, it will take short sellers 8 days to cover their AVEO’s short positions. The short interest to Aveo Pharmaceuticals Inc’s float is 10.95%.

The stock decreased 0.80% or $0.0174 during the last trading session, reaching $2.1626. About 54,510 shares traded. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has risen 351.31% since May 17, 2017 and is uptrending. It has outperformed by 339.76% the S&P500.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $333.37 million. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Ratings Coverage

Among 2 analysts covering AVEO Pharma (NASDAQ:AVEO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AVEO Pharma had 6 analyst reports since December 7, 2017 according to SRatingsIntel. FBR Capital maintained AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on Tuesday, January 16 with “Buy” rating. The firm has “Buy” rating given on Thursday, March 29 by Piper Jaffray. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) earned “Buy” rating by FBR Capital on Monday, February 12. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has “Buy” rating given on Tuesday, March 13 by FBR Capital. FBR Capital maintained AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on Thursday, March 22 with “Buy” rating. FBR Capital maintained the stock with “Buy” rating in Thursday, December 7 report.

More recent AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) news were published by: Seekingalpha.com which released: “3 Things In Biotech, May 9: New AML Therapy Imminent? AVEO Hedges, Rockwell Boosts Iron” on May 10, 2018. Also Fool.com published the news titled: “Here’s Why AVEO Pharmaceuticals Fell as Much as 17% Today” on May 08, 2018. Nasdaq.com‘s news article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within FNB, Comcast, IZEA, AVEO Pharmaceuticals …” with publication date: May 09, 2018 was also an interesting one.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: